RVNC — Revance Therapeutics Share Price
0.000.00%
Last trade - 00:00- $379.67m
- $532.44m
- $234.04m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.17 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -69.57% | ||
| Return on Equity | n/a | ||
| Operating Margin | -129.13% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.41 | 15.32 | 77.8 | 132.56 | 234.04 | 276.8 | 373.12 | 128.84% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to commercialize DAXXIFY in China. Its product/product candidate includes DAXXIFY for glabellar lines indication; DAXXIFY for cervical dystonia indication; RHA Redensity for perioral rhytids indication; RHA 2/ RHA 3/ RHA 4 for facial wrinkles and folds (such as nasolabial folds) indication; DAXXIFY for forehead lines, lateral canthal lines, upper facial lines indication; DAXXIFY for upper limb spasticity indication, and onabotulinumtoxinA biosimilar. The Company has exclusive right to import, market, promote, sell and distribute Teoxane's line of Resilient Hyaluronic Acid dermal fillers.
Directors
- Angus Russell NEC (65)
- Dustin Sjuts PRE (42)
- Mark Foley CEO (55)
- Tobin Schilke CFO (46)
- Aubrey Rankin CEX (45)
- Abhay Joshi COO (57)
- Dwight Moxie SVP (44)
- Jill Beraud IND (60)
- Julian Gangolli IND (64)
- Carey Kolaja IND (48)
- Chris Nolet IND (64)
- Philip Vickers IND (61)
- Olivia Ware IND (64)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- August 10th, 1999
- Public Since
- February 6th, 2014
- No. of Shareholders
- 155
- No. of Employees
- 597
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 104,448,502
- Address
- 1222 Demonbreun Street, Suite 2000, NASHVILLE, 37203
- Web
- https://www.revance.com/
- Phone
- +1 6157247755
- Contact
- Jessica Serra
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for RVNC
Q3 2024 Revance Therapeutics Inc Earnings Release
Similar to RVNC
111
NASDAQ Global Market
ADMA Biologics
NASDAQ Global Market
Alimera Sciences
NASDAQ Global Market
ANI Pharmaceuticals
NASDAQ Global Market
Aquestive Therapeutics
NASDAQ Global Market
FAQ
What is the Revance Therapeutics share price?
As of Today at 16:58 UTC, shares in Revance Therapeutics are trading at $2.66. This share price information is delayed by 15 minutes.
How has the Revance Therapeutics share price performed this year?
Shares in Revance Therapeutics last closed at $2.66 and the price had moved by -90.17% over the past 365 days. In terms of relative price strength the Revance Therapeutics share price has underperformed the S&P500 Index by -92.18% over the past year.
What are the analyst and broker recommendations for Revance Therapeutics?
The overall consensus recommendation for Revance Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Revance Therapeutics dividend yield?
Revance Therapeutics does not currently pay a dividend.
Does Revance Therapeutics pay a dividend?
Revance Therapeutics does not currently pay a dividend.
When does Revance Therapeutics next pay dividends?
Revance Therapeutics does not currently pay a dividend.
How do I buy Revance Therapeutics shares?
To buy shares in Revance Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Revance Therapeutics?
As of the previous close price of $2.66, shares in Revance Therapeutics had a market capitalisation of $277.83m.
Where are Revance Therapeutics shares listed?
Here are the trading details for Revance Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: RVNC
What kind of share is Revance Therapeutics?
Based on an overall assessment of its quality, value and momentum Revance Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Revance Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Revance Therapeutics is $12.82. That is 381.95% above the last closing price of $2.66.
Analysts covering Revance Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$2.10 for the next financial year.
What is the trend in the Revance Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Revance Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -72.88%.
As of the last closing price of $2.66, shares in Revance Therapeutics were trading -60.33% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Revance Therapeutics PE Ratio?
The Revance Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.66.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Revance Therapeutics?
Revance Therapeutics' management team is headed by:
- Angus Russell - NEC
- Dustin Sjuts - PRE
- Mark Foley - CEO
- Tobin Schilke - CFO
- Aubrey Rankin - CEX
- Abhay Joshi - COO
- Dwight Moxie - SVP
- Jill Beraud - IND
- Julian Gangolli - IND
- Carey Kolaja - IND
- Chris Nolet - IND
- Philip Vickers - IND
- Olivia Ware - IND